Abstract
Despite evidence-based guidelines that advocate aggressive management of hyperglycemia, hypertension, and hyperlipidemia, patients with diabetes continue to suffer from high rates of cardiovascular and microvascular complications and can expect a lifespan reduction of 10 to 15 years. Our current inability to effectively and widely translate clinical evidence into usual practice represents a major barrier to reducing the burden of diabetes and its complications. Diabetes care represents a complex interaction between patients (and their families and communities), physicians (and other providers), and the health care system. Because multi-drug regimens are typically required to control hyperglycemia and the diabetes-related risk factors of hypertension and hyperlipidemia, polypharmacy is the natural consequence of providing evidence-based medical care to patients with type 2 diabetes. Within this context, we review the current evidence regarding the following three potential barriers to effective care: 1) Medication adherence in the setting of complex medical regimens, 2) Lack of medication adjustment among patients above risk factor goals, and 3) Limitations of currently organized care systems to manage complex chronic diseases such as diabetes. We also describe recent results of controlled trials of population-level, informatics-based interventions to improve diabetes care.
Keywords: Diabetes, Medication adherence, Clinical inertia, Population management, Evidence-based care, Clinical practice
Current Diabetes Reviews
Title: Overcoming Barriers to Evidence-Based Diabetes Care
Volume: 2 Issue: 2
Author(s): Richard W. Grant and James B. Meigs
Affiliation:
Keywords: Diabetes, Medication adherence, Clinical inertia, Population management, Evidence-based care, Clinical practice
Abstract: Despite evidence-based guidelines that advocate aggressive management of hyperglycemia, hypertension, and hyperlipidemia, patients with diabetes continue to suffer from high rates of cardiovascular and microvascular complications and can expect a lifespan reduction of 10 to 15 years. Our current inability to effectively and widely translate clinical evidence into usual practice represents a major barrier to reducing the burden of diabetes and its complications. Diabetes care represents a complex interaction between patients (and their families and communities), physicians (and other providers), and the health care system. Because multi-drug regimens are typically required to control hyperglycemia and the diabetes-related risk factors of hypertension and hyperlipidemia, polypharmacy is the natural consequence of providing evidence-based medical care to patients with type 2 diabetes. Within this context, we review the current evidence regarding the following three potential barriers to effective care: 1) Medication adherence in the setting of complex medical regimens, 2) Lack of medication adjustment among patients above risk factor goals, and 3) Limitations of currently organized care systems to manage complex chronic diseases such as diabetes. We also describe recent results of controlled trials of population-level, informatics-based interventions to improve diabetes care.
Export Options
About this article
Cite this article as:
Grant W. Richard and Meigs B. James, Overcoming Barriers to Evidence-Based Diabetes Care, Current Diabetes Reviews 2006; 2 (2) . https://dx.doi.org/10.2174/157339906776818604
DOI https://dx.doi.org/10.2174/157339906776818604 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Potential Effect of Carvedilol Against Osteoporosis in Ovariectomized Rats
Current Drug Therapy Contemporary Risk Assessment and Cardiovascular Outcomes in Peripheral Arterial Disease
Cardiovascular & Hematological Disorders-Drug Targets Effect of Colestimide on Reduction of Body Weight and Waist Circumference in Metabolic Syndrome Patients with Cardiovascular Risk Factors
Vascular Disease Prevention (Discontinued) Risk Stratification of Dyslipidemia: Insights from the Framingham Study
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Severe Preeclampsia
Current Women`s Health Reviews Pharma Emerging Market’s Scaning by Look and Feel of its Opportunities and Challenges
Applied Clinical Research, Clinical Trials and Regulatory Affairs Screening of Antihypertensive Drugs for Osteoclastic Acid Secretion and Bone Resorption by Acridine Orange
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Ruptured Renal Artery Aneurysm: Successful Endovascular Therapy with Stent-Graft Placement
Current Medical Imaging GUT Microbiome-GUT Dysbiosis-Arterial Hypertension: New Horizons
Current Hypertension Reviews Cardiovascular and Antidipsogenic Effects of Nesfatin-1
Current Pharmaceutical Design Drug Repositioning for Treatment of Movement Disorders: From Serendipity to Rational Discovery Strategies
Current Topics in Medicinal Chemistry Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Lipid Lowering Therapy in the Elderly: Is there a Benefit?
Current Pharmaceutical Design Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies
Pharmaceutical Nanotechnology The Vasculature as a Target in the Treatment of Pulmonary Emphysema
Current Drug Targets Editorial (Thematic Issue: Current Research, Knowledge and Controversies on High Density Lipoprotein)
Current Medicinal Chemistry Low Baseline Urine Creatinine Excretion Rate Predicts Poor Outcomes among Critically Ill Acute Stroke Patients
Current Neurovascular Research Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway
Current Drug Targets Endothelium and Oxidative Stress: The Pandora's Box of Cerebral (and Non-Only) Small Vessel Disease?
Current Molecular Medicine